Mucosal and systemic immunization against tuberculosis by ISCOMATRIX nano adjuvant co-administered with alginate coated chitosan nanoparticles.
Adjuvant
Chitosan
ISCOMATRIX
Immune response
Nanoparticle
Journal
Iranian journal of basic medical sciences
ISSN: 2008-3866
Titre abrégé: Iran J Basic Med Sci
Pays: Iran
ID NLM: 101517966
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
08
2022
accepted:
30
04
2023
medline:
22
9
2023
pubmed:
22
9
2023
entrez:
22
9
2023
Statut:
ppublish
Résumé
BCG vaccine has no longer been appreciated to immunize against tuberculosis, worldwide, so novel appropriate adjuvants have been dedicated to improve immune responses. This study aimed to evaluate the immunomodulatory effects of ISCOMATRIX as an adjuvant to stimulate potent humoral and cellular immune responses of the PPE17 loaded alginate coated nanoparticles through subcutaneous and intranasal vaccination. Size, polydispersity index, and morphology of the resulting colloidal particles were explored by dynamic light scattering (DLS). The cellular and/or humoral immune stimulation properties of ISCOMATRIX adjuvant were measured by measuring the level of IFNγ, IL-4, IL-17, and TGFβ in spleen cell cultures and IgG1 and IgG2a in serum and sIgA in nasal lavage of immunized mice, respectively. The spherical cage-like particles of ISCOMATRIX adjuvant have optimal size of 59±6 nm appropriate for an immune adjuvant vaccine. ISCOMATRIX induced robust Th1 (IFN-γ) and IL-17 cytokine response also significant IgG2a and IgG1antibodies in both subcutaneous and intranasal routes and elicited mucosal sIgA response when administered intranasally. As a booster for BCG, ISCOMATRIX induced immune responses only in subcutaneous route. These findings indicate that ISCOMATRIX is a promising adjuvant with the potential for increasing cellular and humoral immunity both after subcutaneous and intranasal administration.
Identifiants
pubmed: 37736514
doi: 10.22038/IJBMS.2023.67564.14806
pmc: PMC10510487
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1162-1167Déclaration de conflit d'intérêts
The authors state that they have no competing interests.
Références
Infect Immun. 2007 Jan;75(1):408-16
pubmed: 17074845
Clin Exp Immunol. 1998 Aug;113(2):235-43
pubmed: 9717973
Semin Respir Crit Care Med. 2018 Jun;39(3):271-285
pubmed: 30071543
J Med Microbiol. 2012 Jul;61(Pt 7):935-943
pubmed: 22442293
Microorganisms. 2019 Aug 12;7(8):
pubmed: 31409028
Int J Pharm. 2014 Nov 20;475(1-2):1-8
pubmed: 25148732
Drug Deliv Transl Res. 2013 Feb;3(1):100-9
pubmed: 23316448
Arch Pharm Res. 2013 Aug;36(8):981-92
pubmed: 23568383
Vaccine. 2004 Jun 23;22(19):2391-5
pubmed: 15193400
Int J Nanomedicine. 2019 May 01;14:3129-3143
pubmed: 31118627
Expert Rev Vaccines. 2007 Oct;6(5):761-72
pubmed: 17931156
Vaccine. 2007 Mar 30;25(14):2541-4
pubmed: 17240491
Artif Cells Nanomed Biotechnol. 2018;46(sup2):587-593
pubmed: 29688038
Blood. 2005 Mar 15;105(6):2465-72
pubmed: 15546948
Int J Pharm. 2000 Mar 10;196(2):135-9
pubmed: 10699704
Life Sci. 2021 Oct 1;282:119806
pubmed: 34252419
J Immunol. 1991 Jan 15;146(2):431-7
pubmed: 1987271
J Immunol. 2009 Feb 1;182(3):1253-9
pubmed: 19155470
Vaccine. 2000 Aug 15;19(1):122-31
pubmed: 10924794
J Immunol. 2011 Jul 1;187(1):55-63
pubmed: 21613613
Int J Infect Dis. 2021 Dec;113 Suppl 1:S7-S12
pubmed: 33716195
J Leukoc Biol. 1998 Dec;64(6):713-23
pubmed: 9850152
Adv Drug Deliv Rev. 2005 Jan 10;57(3):465-74
pubmed: 15560952
J Clin Med. 2020 Aug 17;9(8):
pubmed: 32824563
Immunol Cell Biol. 2012 May;90(5):540-52
pubmed: 21894173